Fig. 2

Reasons for ART regimen discontinuation identified from healthcare provider notes, lab results, and diagnoses, by ART regimen (DTG/3TC, BIC/FTC/TAF, DTG 3DR). 3DR, 3-drug regimen; 3TC, lamivudine; ART, antiretroviral therapy; BIC, bictegravir; DTG, dolutegravir; Dx, diagnosis; FTC, emtricitabine; mL, milliliter; TAF, tenofovir alafenamide; VL, viral load. ^a Last VL > 200 copies/mL, adverse diagnosis/side effect (i.e., new mental health, liver, renal or bone comorbidity diagnosed within 21 days before discontinuation, or as noted), lab abnormality (i.e., alkaline phosphatase [ALP], alanine transaminase [ALT], aspartate transaminase [AST] or bilirubin > 3 times the upper limits of normal within 21 days of discontinuation). ^b Simplification; access issues; non-adherence; treatment gap; patient/provider choice; any other reason noted